Modified release pharmaceutical compositions

1. A multiparticulate modified release pharmaceutical composition comprising:

a first portion comprising

at least one active ingredient comprising a calcium channel blocker,

at least one surfactant, and

at least one release modifying agent; and

a second portion mixed with the first portion, the second portion comprising

at least one active ingredient comprising a calcium channel blocker, and

optionally, at least one release modifying agent,

the second portion having a different release profile than the first portion;

the first portion having a form comprising a plurality of at least one selected from pellets, granules, microparticles, nanoparticles, and a combination thereof, the second portion having a form comprising a plurality of matrix granules,

wherein the active ingredient of the first portion is released at pH above about 5.5, and release of the active ingredient of the second portion is pH independent.

2. The composition as claimed in claim 1 , wherein the calcium channel blocker is selected from the group consisting of Nisoldipine, Nifedipine, Nitrendipine, Nicardipine, Nimodipine, Felodipine, Amlodipine, Aranidipine, Azelnidipine, Barnidipine, Benidipine, Cilnidipine, Clevidipine, Efonidipine, Lacidipine, Lercanidipine, Manidipine, Nilvadipine, Nitrendipine, Pranidipine, and combinations thereof.

3. The composition as claimed in claim 1 , wherein the active ingredient present in the first portion and the second portion are the same.

4. The composition as claimed in claim 1 , wherein the first portion provides the release of the active ingredient in a modified manner and the second portion provides the release of the active ingredient in an extended manner.

5. The composition as claimed in claim 1 , wherein the first portion provides the release of the active ingredient in a delayed manner and the second portion provides the release of the active ingredient in an extended manner.

6. The composition as claimed in claim 1 , wherein the first portion of the active ingredient is released in a delayed or extended manner and the second portion of the active ingredient is released immediately.

7. The composition as claimed in claim 1 , further comprising an active ingredient present in the second portion selected from the group consisting of an angiotensin-converting enzyme inhibitor, beta-blocker, angiotensin receptor blocker, anti-angina agent, anti-arrhythmic agent, anti-ischaemic agent, vasodilator, bronchodilator, hypolipidaemic agent, antidiabetic, and combinations thereof.

8. The composition as claimed in claim 1 , further comprising an active ingredient in at least one of the first portion or second portion selected from the group consisting of an angiotensin-converting enzyme inhibitor, beta-blocker, angiotensin receptor blocker, anti-angina agent, anti-arrhythmic agent, anti-ischaemic agent, vasodilator, bronchodilator, hypolipidaemic agent, antidiabetic, and combinations thereof.

9. The composition as claimed in claim 1 , wherein the first portion of the composition is provided in the form of delayed release pellets and the second portion of the composition is provided in the form of matrix granules.

10. The composition as claimed in claim 1 , wherein the active ingredient present in the first portion and the second portion is Nisoldipine.

11. The composition as claimed in claim 10 , wherein the composition is in the form of multiparticulate tablet or capsule.

12. The composition as claimed in claim 10 , wherein the first portion of the composition is provided in the form of delayed release pellets and the second portion of the composition is provided in the form of matrix granules and said composition exhibits a dissolution profile such that

after about 2 hours, about 5% to about 50% of Nisoldipine is released,

after about 4 hours, about 20% to about 90% of Nisoldipine is released,

after about 8 hours, about 40% to about 100% of Nisoldipine is released, and

after about 12 hours, more than about 80% of Nisoldipine is released.

13. The composition as claimed in claim 10 , wherein the composition comprises about 2.0% to about 20% by weight of Nisoldipine, about 10% to about 50% by weight of release modifying agents, 2% to about 90% by weight of diluents, about 2% to about 20% by weight of binders, about 0.2% to about 3.0% by weight of lubricants, about 0.2% to about 5% by weight of glidants, about 2.0 to about 20% by weight of coating agents.

14. The composition as claimed in claim 7 , wherein the beta-blocker is selected from the group consisting of Acebutolol, Atenolol, Betaxolol, Bisoprolol, Carteolol, Esmolol, Labetalol, Metoprolol, Timolol, Nadolol, Oxprenolol, Penbutolol, Pindolol, Propranolol, Sotalol, and combinations thereof; the angiotensin receptor blocker is selected from the group consisting of Valsartan, Telmisartan, Irbesartan, Losartan, Candesartan, Olmesartan, and combinations thereof; the angiotensin-converting enzyme inhibitor is selected from the group consisting of benazepril, captopril, cilazapril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, pharmaceutically acceptable salts thereof, and combinations thereof; the insulin sensitizer is a thiazolidinedione selected from the group consisting of Troglitazone, Ciglitazone, Pioglitazone, Rosiglitazone, and combinations thereof; the antidiabetic is a biguanide or an insulin sensitizer selected from the group consisting of Troglitazone, Ciglitazone, Pioglitazone, Rosiglitazone, and combinations thereof, or an insulin secretagogue selected from the group consisting of Glipizide, Glimepiride, Glibenclamide, Gliclazide, and combinations thereof.

15. A multiparticulate modified release tablet comprising:

a first portion comprising

at least one active ingredient comprising Nisoldipine,

at least one surfactant, and

at least one release modifying agent; and

a second portion mixed with the first portion, the second portion comprising

at least one active ingredient comprising Nisoldipine, and

optionally, at least one release modifying agent,

the second portion having a different release profile than the first portion;

the first portion having a form comprising a plurality of at least one selected from pellets, granules, microparticles, nanoparticles, and a combination thereof, the second portion having a form comprising a plurality of matrix granules,

wherein the active ingredient of the first portion is released at pH above about 5.5, and release of the active ingredient of the second portion is pH independent.

16. A multiparticulate modified release pharmaceutical composition comprising:

a first portion comprising

at least one active ingredient comprising a calcium channel blocker loaded on an inert inner core,

a delayed release coat, and

optionally, a separating coat between the inner core and delayed release coat; and

a second portion mixed with the first portion, the second portion comprising

at least one active ingredient comprising a calcium channel blocker, and

one or more release modifying polymers,

the second portion having a different release profile than the first portion;

the first portion having a form comprising a plurality of at least one selected from pellets, granules, microparticles, nanoparticles, and a combination thereof, the second portion having a form comprising a plurality of matrix granules,

wherein the active ingredient of the first portion is released at pH above about 5.5, and release of the active ingredient of the second portion is pH independent.

17. A multiparticulate modified release pharmaceutical composition comprising:

a first portion comprising

at least one active ingredient comprising Nisoldipine loaded on an inert inner core,

a delayed release coat, and

optionally, a separating coat between the inner core and delayed release coat; and

a second portion mixed with the first portion, the second portion comprising

at least one active ingredient comprising Nisoldipine, and

optionally, at least one release modifying agent,

the second portion having a different release profile than the first portion;

the first portion having a form comprising a plurality of at least one selected from pellets, granules, microparticles, nanoparticles, and a combination thereof, the second portion having a form comprising a plurality of matrix granules,

wherein said composition exhibits a dissolution profile such that

after about 2 hours, about 5% to about 50% of Nisoldipine is released,

after about 4 hours, about 20% to about 90% of Nisoldipine is released,

after about 8 hours, about 40% to about 100% of Nisoldipine is released, and

after about 12 hours, more than about 80% of Nisoldipine is released,

wherein the active ingredient of the first portion is released at pH above about 5.5, and release of the active ingredient of the second portion is pH independent.

18. The composition as claimed in claim 1 , wherein the surfactant is selected from the group consisting of fatty acids, polysorbate 80, alkyl sulfates, sodium lauryl sulfate, sodium dodecyl sulfate, citric acid, and mixtures thereof.

19. The composition as claimed in claim 1 , wherein the release modifying agent is selected from (a) one or more water soluble materials, (b) one or more water insoluble materials, (c) one or more water swellable materials, and combinations thereof.

20. A process for preparation of the multiparticulate modified release pharmaceutical composition as claimed in claim 16 , comprising:

preparing the first portion comprising the active ingredient loaded on the inert inner core, the delayed release coat and optionally the separating coat between the inner core and delayed release coat;

preparing the second portion comprising the active ingredient and one or more release modifying polymers; and

formulating the first portion and the second portion into the multiparticulate dosage form.

21. The process as claimed in claim 20 , wherein the inert inner core is non-pareil seeds, sugar spheres, or a combination thereof.

22. The process as claimed in claim 20 , wherein the delayed release coat comprises enteric coating polymers.

23. The process as claimed in claim 22 , wherein the enteric coating polymer is a pH dependent polymer, pH independent polymer, or combinations thereof.

24. The process as claimed in claim 20 , wherein the composition is in the form of a multiparticulate tablet.

25. A multiparticulate modified release pharmaceutical composition comprising:

a first portion comprising

at least one active ingredient comprising a calcium channel blocker,

at least one surfactant, and

at least one release modifying agent; and

a second portion mixed with the first portion, the second portion comprising

at least one active ingredient selected from the group consisting of calcium channel blocker, angiotensin-converting enzyme inhibitor, beta-blocker, angiotensin receptor blocker, anti-angina agent, anti-arrhythmic agent, anti-ischaemic agent, vasodilator, bronchodilator, hypolipidaemic agent, antidiabetic, and combinations thereof, and

optionally, at least one release modifying agent,

the second portion having a different release profile than the first portion;

the first and second portion each independently having a form comprising a plurality of at least one selected from pellets, granules, microparticles, nanoparticles and a combination thereof,

wherein the active ingredient of the first portion is released at pH above about 5.5, and release of the active ingredient of the second portion is pH independent.